Drugs / EP1300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01169077 | Aug 2010 → Jul 2012 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP1300 | “The primary objective of this study is to evaluate the safety, reactogenicity and tolerability of the EP1300 (DNA) vaccine administered via electroporation in healthy adult volunteers.” NCT01169077 ↗ |
| Modality | Vaccine | “EP-1300 is a polyepitope plasmid DNA vaccine expressing 38 cytotoxic T cell epitopes and 16 helper T cell epitopes derived from P. falciparum antigens expressed predominantly...” PMID 27697302 ↗ Sep 2016 |
| Route | Other | “Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using...” NCT01169077 ↗ |